Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma
Glioblastoma (GBM) is an extremely aggressive tumor of the central nervous system, with a
prognosis of 12–15 months and just 3–5% of survival over 5 years. This is mainly because …
prognosis of 12–15 months and just 3–5% of survival over 5 years. This is mainly because …
Neuronal and tumourigenic boundaries of glioblastoma plasticity
Glioblastoma (GBM) remains the most lethal primary brain cancer largely due to recurrence
of treatment-resistant disease. Current therapies are ultimately ineffective as GBM tumour …
of treatment-resistant disease. Current therapies are ultimately ineffective as GBM tumour …
The phenotypes of proliferating glioblastoma cells reside on a single axis of variation
Although tumor-propagating cells can be derived from glioblastomas (GBM) of the proneural
and mesenchymal subtypes, a glioma stem-like cell (GSC) of the classic subtype has not …
and mesenchymal subtypes, a glioma stem-like cell (GSC) of the classic subtype has not …
ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer
S Nouruzi, D Ganguli, N Tabrizian, M Kobelev… - Nature …, 2022 - nature.com
Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …
leads to the emergence of resistant tumors characterized by lineage plasticity and …
ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem …
Z Gao, J Xu, Y Fan, Z Zhang, H Wang, M Qian… - Journal of Experimental …, 2022 - Springer
Background Intratumoral heterogeneity is the primary challenge in the treatment of
glioblastoma (GBM). The presence of glioma stem cells (GSCs) and their conversion …
glioblastoma (GBM). The presence of glioma stem cells (GSCs) and their conversion …
The adaptive transition of glioblastoma stem cells and its implications on treatments
Glioblastoma is the most malignant tumor occurring in the human central nervous system
with overall median survival time< 14.6 months. Current treatments such as chemotherapy …
with overall median survival time< 14.6 months. Current treatments such as chemotherapy …
FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-κB axis
Z Chen, S Wang, HL Li, H Luo, X Wu, J Lu, HW Wang… - Molecular Therapy, 2022 - cell.com
Proneural (PN) to mesenchymal (MES) transition (PMT) is a crucial phenotypic shift in
glioblastoma stem cells (GSCs). However, the mechanisms driving this process remain …
glioblastoma stem cells (GSCs). However, the mechanisms driving this process remain …
Oncogenic and tumor-suppressive functions of NOTCH signaling in glioma
E Parmigiani, V Taylor, C Giachino - Cells, 2020 - mdpi.com
Although the role of NOTCH signaling has been extensively studied in health and disease,
many questions still remain unresolved. Being crucial for tissue homeostasis, NOTCH …
many questions still remain unresolved. Being crucial for tissue homeostasis, NOTCH …
ASCL1 is a MYCN-and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry
A heritable polymorphism within regulatory sequences of the LMO1 gene is associated with
its elevated expression and increased susceptibility to develop neuroblastoma, but the …
its elevated expression and increased susceptibility to develop neuroblastoma, but the …
Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours
The poor transport of molecular and nanoscale agents through the blood–brain barrier
together with tumour heterogeneity contribute to the dismal prognosis in patients with …
together with tumour heterogeneity contribute to the dismal prognosis in patients with …